Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients

被引：0
作者：
Dirk R. Kuypers
Henrik Ekberg
Josep Grinyó
Björn Nashan
Flavio Vincenti
Paul Snell
Richard D. Mamelok
Rene M. Bouw
机构：
[1] University Hospitals Leuven,Department of Nephrology
[2] University of Lund,Department of Transplantation
[3] Hospital de Bellvitge,Department of Nephrology
[4] University Medical Center Hamburg-Eppendorf,Department of Hepatobiliary Surgery and Visceral Transplantation
[5] University of California at San Francisco,Department of Kidney Transplantation
[6] Roche Products Ltd,Department of Clinical Pharmacology
[7] Mamelok Consulting,Department of Nephrology and Renal Transplantation
[8] University Hospitals Leuven,undefined
[9] University of Leuven,undefined
来源：
Clinical Pharmacokinetics | 2009年 / 48卷
关键词：
Acute Rejection; Mycophenolate Mofetil; Enterohepatic Recirculation; Target Trough Concentration; Mycophenolate Mofetil Dose;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: The pharmacokinetics of mycophenolic acid (MPA) are complex, with large interindividual variability over time. There are also well documented interactions with ciclosporin, and assessment of MPA exposure is therefore necessary when reducing or stopping ciclosporin therapy. Here we report on the pharmacokinetic and pharmacodynamic behaviour of MPA in renal transplant patients on standard dose, reduced dose and no ciclosporin.
引用
收藏
页码：329 / 341
页数：12
相关论文
共 99 条
  • [1] Halloran P.F.(2004)Immunosuppressive drugs for kidney transplantation N Engl J Med 351 2715-29
  • [2] Sollinger H.W.(1995)Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group Lancet 345 1321-5
  • [3] Benigni A.(1995)U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 60 225-32
  • [4] Bruzzi I.(1996)A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1029-37
  • [5] Mister M.(1999)Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year Kidney Int 55 674-85
  • [6] Luke R.G.(1991)Mechanism of cycloporine-induced hypertension Am J Hypertens 4 468-71
  • [7] Markell M.S.(1993)Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients Am J Kidney Dis 22 233-9
  • [8] Sumrani N.(1984)Cyclosporine-associated chronic nephropathy N Engl J Med 311 699-705
  • [9] DiBenedetto A.(2002)Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study Transplantation 74 1725-34
  • [10] Myers B.D.(2005)Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study Transplantation 79 466-75
12345678910